Brain Navi NaoTrac, the Brain Surgical Navigation Robot, Received European CE Mark Approval in 2021

Brain Navi Biotechnology Co., Ltd.

PR93252

 

ZHUBEI CITY, Taiwan, Nov. 23, 2021 /PRNewswire=KYODO JBN/ --

 

Brain Navi Biotechnology, a Taiwan-based startup specializing in innovative

navigation robots, received CE mark approval for brain surgery procedures in Q1

2021 for its NaoTrac, a robotic-assisted surgical robot. As the next step Brain

Navi Biotechnology is planned to be submitted for FDA clearance.

 

"Long surgery times, high concentration, and precision requires a lot of

physical endurance for neurosurgeons in every procedure. This can in turn

affect the surgery's performance," said Jerry Chen, M.D., the CEO of Brain Navi

Biotechnology. "Utilizing NaoTrac to navigate in the cranial not only reduces

anesthesia time, but also improves the patient's well-being by means of less

invasive interventions."

 

The NaoTrac is equipped with a high-precision navigation system; the patient

registration is performed with a non-contact machine vision process. Surgical

instruments are recognized in seconds with its patented registration algorithm.

 

Surgeons can choose the surgery pathway with a 3D vision for precise anatomical

location during the pre-operating planning preparation and monitor the robot

during the entire procedure. The unique navigation procedure allows the surgeon

to plan and let Surgical Navigation act as an assistant.

 

"Robotics and artificial intelligence are the future of healthcare, with

remarkable potential to not only advance patient care, but increase access to

these benefits. Its essential is to increase the degree of accuracy of the

surgery," said Shinn-Zong Lin, M.D. PhD., Superintendent of Hualien Tzu-Chi

Medical Center. Dr. Lin is also an honored fellow of AAAS (American Association

for the Advancement of Science). Dr. Lin also mentioned that "The technology

used by Surgical Navigation Robot can be used in various medical fields, such

as immunotherapy, cell transplant, microchip implantation, etc., where a high

degree of accuracy is required. Therefore, Surgical Navigation Robot not only

has the ability to execute EVD or tumor resection, but it also has the

potential to collaborate within these fields."

 

All this robotic technology is based on a SMART (Surface Mapping

Auto-Registration Technology) platform, and is patented by Brain Navi

Biotechnology. It merges machine vision, robotic technology, and algorithms to

achieve "real-time imaging", "precise surgery" and "minimally invasive

outcomes" during surgery. The SMART platform is a highly-extensible technology,

besides neurosurgery, Brain Navi Biotechnology has an Industry-Academia

Cooperation cooperating with Chenggong University of Taiwan to develop a

project for liver ablation navigation. The SMART platform is heading to the

application of the world's top 10 cancer early treatments as the research and

development direction.

 

Brain Navi Biotechnology is currently searching for strategic partners and

early adopters. Brain Navi Biotechnology will hold a LIVE broadcast to share

THE FUTURE OF ROBOTIC SURGERIES during the 2021 Healthcare EXPO in Taiwan on

December 2nd to 5th, 2021. For more information, visit

https://brainnavi.com/product/naotrac/

 

 

SOURCE: Brain Navi Biotechnology Co., Ltd.

 

Image Attachments Links:

 

   Link: http://asianetnews.net/view-attachment?attach-id=408541

 

   Caption: Brain Navi NaoTrac, the Brain Surgical Navigation Robot Human trials

 

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中